clinical trial · NCT04656288
A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the Blood
HealthyBI 764198 - Formula ABI 764198 - Formula BBI 764198 - Formula CBI 764198 - Formula D
brief summary
BI 764198 is intended to be used in patients hospitalized for COVID-19 at risk of respiratory complications. The present trial will investigate the relative bioavailability of BI 764198 administered as capsules versus tablets in a first part, and the relative bioavailability and food effect of four oral formulations: the newly developed tablet formulation under fed and fasted conditions as well as suspension from capsules and suspension from tablets in a second part.
started
Jan 15, 2021
primary completion
Mar 15, 2021
completion
Mar 15, 2021
last updated
Jul 6, 2026
official title
A Two-part Phase I Trial Investigating the Relative Bioavailability and Food Effect of Different Oral Formulations of BI 764198 in Healthy Subjects (an Open-label, Single-dose, Randomised, Crossover Study)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol